Salute e Benessere
Onconic Therapeutics Announces Positive Phase 3 Results for JAQBO at Digestive Diseases Week 2024
"We are encouraged by the positive results of the ZERO-1 study, which highlight the efficacy and safety of JAQBO for patients with erosive esophagitis," said John Kim , Ph.D., CEO of Onconic Therapeutics. "The recent approval by the MFDS of Korea is a significant milestone for Onconic Therapeutics. We are hopeful that JAQBO can improve patient care globally by providing rapid and sustained relief from symptoms, and we are committed to pursuing its development for broader international markets."
In March 2023 , JAQBO was licensed to Livzon Pharmaceutical Group, the leading pharmaceutical company in China , for development and commercialization in the Greater China market.
Zastaprazan, developed by Onconic Therapeutics, was approved for the treatment of erosive esophagitis under the brand name JAQBO by the Ministry of Food and Drug Safety (MFDS) of Korea in
April 2024 .
Onconic Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs. The company is dedicated to improving patient outcomes and providing innovative healthcare solutions for cancer and gastrointestinal disorders.
Logo - https://mma.prnewswire.com/media/2397512/4731064/Onconic_Therapeutics_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/onconic-therapeutics-announces-positive-phase-3-results-for-jaqbo-at-digestive-diseases-week-2024-302157784.html